Atlas Venture
SelectiveCambridge, MALast fund filed August 2025Biotechnology, Pharmaceuticals
Cambridge, MALast fund filed August 2025Biotechnology, Pharmaceuticals
0 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Atlas Venture Opportunity Fund Ill, L.P. | August 2025 | $400.0M | $400.0M | 84 |
| Atlas Venture Fund XIV, L.P. | December 2024 | $450.0M | $450.0M | 84 |
| Atlas Venture Fund XIII, L.P. | March 2022 | $450.0M | $450.0M | 87 |
| Atlas Venture Opportunity Fund II, L.P. | September 2021 | $300.0M | $300.0M | 69 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. Form D carries no per-investor amount, so a firm’s own cheque is not recoverable here.
6 partners are named across this firm’s filings, 0 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats, 24mo |
|---|---|---|---|
| Jean-Francois Formela | Slowing | None listed | 1 |
| Michael GladstoneOn the current fund | Slowing | Biotechnology | 1 |
| Bruce BoothOn the current fund | Quiet | Biotechnology | 0 |
| David Grayzel | Quiet | None listed | 0 |
| Jason RhodesOn the current fund | Quiet | None listed | 0 |
| Kevin BittermanOn the current fund | Quiet | Biotechnology | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. On a firm it is the total across its partners, so an active firm may be four partners taking one seat each rather than one person moving fast. It undercounts partners who invest without taking a board seat, and Form D lags a closing by weeks — so Quiet means the paperwork is quiet, not the person.